StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $61.42 | $61.26 | -0.26% | 0.6M |
| 05-12 | $60.02 | $61.98 | +3.27% | 0.4M |
| 05-13 | $60.50 | $60.47 | -0.05% | 0.5M |
| 05-14 | $60.47 | $61.80 | +2.20% | 0.7M |
| 05-15 | $60.00 | $59.65 | -0.58% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for GRAL.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for GRAL.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $40.78M | $147.17M | $103.58M | $67.38M |
Operating Income | $-135.76M | $-562.16M | $-437.75M | $-312.46M |
Net Income | $-93.19M | $-408.35M | $-309.18M | $-113.98M |
EPS (Diluted) | $-2.29 | $-11.11 | $-8.73 | $-6.28 |
Total Assets | $2.80B | $2.92B | $2.60B | $2.70B |
Total Liabilities | $302.79M | $344.15M | $361.07M | $387.91M |
Cash & Equivalents | $69.34M | $249.73M | $126.89M | $127.43M |
Free Cash Flow OCF − CapEx | $-87.49M | $-299.92M | $-236.04M | $-172.41M |
Shares Outstanding | 41.13M | 40.33M | 36.16M | 36.05M |
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.